Subject: viral hepatitis | Pegylated interferon, discontinuation, indigenous population, longitudinal study, sustained virologic response. | pegylated interferon | longitudinal study | indigenous population | RC955-962 | discontinuation | clinical investigation; infectious disease; | Original Research Article | sustained virologic response | Arctic medicine. Tropical medicine
mesheuropmc: digestive system diseases | virus diseases
Background. There have been few reports of hepatitis C virus (HCV) treatment results with interferon-based regimens in indigenous populations.Objective. To determine interferon-based treatment outcome among Alaska Native and American Indian (AN/AI) population.Design. In... View more
1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Pegylated alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975 82.
2. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Pegylated alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346 55.
3. Hu KQ, Freilich B, Brown RS, Brass C, Jacobson IM. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol. 2011;45:720 6.
4. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 2007;102:2181 8.
5. Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat. 2011;18:e134 43.
6. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265 71.
7. Jeffers L, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a [40kd] and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004; 39:1702 8.
8. Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006;42:82 91.
9. Ge D, Fellay J, Thompson AJ, Simons JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399 401.
10. Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos NM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci. 2014;59:3043 52.